Cost-Effectiveness Analysis of Lesinurad/Allopurinol Versus Febuxostat for the Management of Gout/Hyperuricemia in Italy

[1] Zhang W(2006)EULAR evidence based recommendations for gout. Part II: management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT) Ann Rheum Dis 65 1312-1324

[2] Doherty M(2000)The interaction between uric acid level and other risk factors on the development of gout among asymptomatic hyperuricemic men in a prospective study J Rheumatol 27 1501-1505

[3] Bardin T(2004)Prevalence of musculoskeletal conditions in an Italian population sample: results of a regional community-based study. I. The MAPPING study Clin Exp Rheumatol 23 819-828

[4] Pascual E(2006)Epidemiology, risk factors, and lifestyle modifications for gout Arthritis Res Ther 8 S2-S62

[5] Barskova V(2008)Gout: an evidence-based review J Clin Rheumatol. 14 S55-2432

[6] Conaghan P(2004)Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis J Rheumatol 31 2429-2461

[7] Lin KC(2005)Febuxostat compared with allopurinol in patients with hyperuricemia and gout N Engl J Med 353 2450-822

[8] Lin HY(2008)The disutility of chronic gout Qual Life Res 17 815-175

[9] Chou P(2015)Cost-effectiveness analysis of allopurinol versus febuxostat in chronic gout patients: a US payer perspective J Manag Care Spec Pharm 21 165-502

[10] Salaffi F(2009)The half-cycle correction: banish rather than explain it Med Decis Mak 29 500-490

[1] Zhang W(2006)EULAR evidence based recommendations for gout. Part II: management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT) Ann Rheum Dis 65 1312-1324

[2] Doherty M(2000)The interaction between uric acid level and other risk factors on the development of gout among asymptomatic hyperuricemic men in a prospective study J Rheumatol 27 1501-1505

[3] Bardin T(2004)Prevalence of musculoskeletal conditions in an Italian population sample: results of a regional community-based study. I. The MAPPING study Clin Exp Rheumatol 23 819-828

[4] Pascual E(2006)Epidemiology, risk factors, and lifestyle modifications for gout Arthritis Res Ther 8 S2-S62

[5] Barskova V(2008)Gout: an evidence-based review J Clin Rheumatol. 14 S55-2432

[6] Conaghan P(2004)Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis J Rheumatol 31 2429-2461

[7] Lin KC(2005)Febuxostat compared with allopurinol in patients with hyperuricemia and gout N Engl J Med 353 2450-822

[8] Lin HY(2008)The disutility of chronic gout Qual Life Res 17 815-175

[9] Chou P(2015)Cost-effectiveness analysis of allopurinol versus febuxostat in chronic gout patients: a US payer perspective J Manag Care Spec Pharm 21 165-502

[10] Salaffi F(2009)The half-cycle correction: banish rather than explain it Med Decis Mak 29 500-490